The Effects of Atorvastatin in Patients With Atherosclerosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00115817|
Recruitment Status : Completed
First Posted : June 27, 2005
Last Update Posted : April 24, 2007
The purpose of the study is to evaluate the effects of Atorvastatin.
The investigators want to find out if atorvastatin has other helpful qualities. The investigators are interested in finding out if medicines like atorvastatin are useful even in people who do not have high levels of bad cholesterol and would like to understand other mechanisms by which this medicine helps prevent further blood vessel disease.
- Atorvastatin reduces Rho kinase activity (in leukocytes) rapidly, within days, in patients with atherosclerosis.
- Any decrease in Rho kinase activity with statin therapy will be accompanied by improvement in familiar markers of atherosclerosis.
|Condition or disease||Intervention/treatment||Phase|
|Atherosclerosis||Drug: Atorvastatin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||36 participants|
|Intervention Model:||Factorial Assignment|
|Official Title:||The Effects of Atorvastatin on the Rho/Rho Kinase Pathway in Patients With Atherosclerosis|
|Study Start Date :||June 2005|
|Study Completion Date :||March 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00115817
|United States, Massachusetts|
|Brigham and Womens Hospital|
|Boston, Massachusetts, United States, 02115|
|Principal Investigator:||Andrew Selwyn, MD||Brigham and Womens Hospital|